ICON Clinical Research
ICON is a global leader in clinical research, dedicated to accelerating the development of drugs and devices that save lives and improve quality of life. They provide comprehensive consulting, development, and commercialization services across various therapeutic areas, with a focus on reducing time to market, cost, and increasing quality. ICON is committed to innovation, quality, and making a positive impact through their ICON Cares ESG program. They also offer specialized solutions including clinical trial management, data management, biostatistics, medical affairs, pharmacovigilance, and innovative technologies for clinical trials. ICON actively engages in real-world evidence generation, data mapping, and digital disruption technologies to enhance clinical research and healthcare decision-making. The company participates in webinars, publishes insights, and maintains a strong focus on transparency, ethics, and regulatory compliance.
Industries
Nr. of Employees
Very Large (1000+)
ICON Clinical Research
South County Business Park, Leopardstown, Dublin 18, Ireland
Products
AI system for forecasting post-marketing regulatory requirements
An AI-enabled predictive system that analyses regulatory databases and real-world drug data to forecast post-marketing study requirements and inform mitigation strategies.
AI-driven site identification and selection tools
Software-enabled tools that integrate and interrogate multiple data sources to support site feasibility and selection decisions using AI and predictive analytics.
AI system for forecasting post-marketing regulatory requirements
An AI-enabled predictive system that analyses regulatory databases and real-world drug data to forecast post-marketing study requirements and inform mitigation strategies.
AI-driven site identification and selection tools
Software-enabled tools that integrate and interrogate multiple data sources to support site feasibility and selection decisions using AI and predictive analytics.
Services
Comprehensive outsourcing across the trial lifecycle including protocol development, study start-up, monitoring, data management, biostatistics and regulatory support.
AI/ML-driven services for site selection, study start-up automation, resource forecasting, document management and post-marketing forecasting using real-world data.
Bioanalytical and central laboratory testing to support clinical trials and precision medicine initiatives, including specialty assay capabilities and integration with clinical operations.
Imaging protocol design, quantitative image analysis, radiomics and volumetric tumour assessments for use as trial endpoints and biomarker development.
Regulatory strategy, submission support and intelligence covering global and regional requirements, pediatric planning and legislative compliance.
Independent QA audits and advisory services for GCP, GLP, GCLP, GMP, vendor qualification, SDLC and computer validation to support inspection readiness.
Comprehensive outsourcing across the trial lifecycle including protocol development, study start-up, monitoring, data management, biostatistics and regulatory support.
AI/ML-driven services for site selection, study start-up automation, resource forecasting, document management and post-marketing forecasting using real-world data.
Bioanalytical and central laboratory testing to support clinical trials and precision medicine initiatives, including specialty assay capabilities and integration with clinical operations.
Imaging protocol design, quantitative image analysis, radiomics and volumetric tumour assessments for use as trial endpoints and biomarker development.
Regulatory strategy, submission support and intelligence covering global and regional requirements, pediatric planning and legislative compliance.
Independent QA audits and advisory services for GCP, GLP, GCLP, GMP, vendor qualification, SDLC and computer validation to support inspection readiness.
Expertise Areas
- Clinical trial management (Phase I–IV)
- Real-world data and real-world evidence
- Database mapping and RWD feasibility assessment
- Clinical data management and biostatistics
Key Technologies
- AI and machine learning
- Real-world data integration
- Predictive analytics
- Radiomics and quantitative imaging analysis
News & Updates
ICON's CEO Dr. Steve Cutler will present at the William Blair conference on June 4, 2025.
The report details ICON’s ESG initiatives and progress.
A survey of biotech and pharma professionals highlights challenges and opportunities in obesity drug development.
Quarter one revenue was $2,001.3 million with an adjusted EBITDA of $390.7 million.
Partnership to utilize participant management and payments platform.
Full year net business wins of $9,974 million.
ICON's CEO Dr. Steve Cutler will present at the William Blair conference on June 4, 2025.
The report details ICON’s ESG initiatives and progress.
A survey of biotech and pharma professionals highlights challenges and opportunities in obesity drug development.
Quarter one revenue was $2,001.3 million with an adjusted EBITDA of $390.7 million.
Partnership to utilize participant management and payments platform.
Full year net business wins of $9,974 million.